fibroblast activation protein inhibitor (Vantia Therapeutics)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug Namefibroblast activation protein inhibitor (Vantia Therapeutics)
Drug Alias NameFAP inhibitors (Vantia)fibroblast activation protein inhibitors (Vantia)FE-999040
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFibroblast activation protein alpha inhibitors
TargetsProlyl endopeptidase FAP
Therapy Area/IndicationsFibrosisInflammatory Bowel DiseasesNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesVantia Therapeutics Ltd.
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesVantia Therapeutics Ltd.
Active IndicationsN/A
Inactive IndicationsFibrosisInflammatory Bowel DiseasesNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A